<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918251</url>
  </required_header>
  <id_info>
    <org_study_id>CRFSJ00170</org_study_id>
    <secondary_id>CRFSJ00171</secondary_id>
    <nct_id>NCT04918251</nct_id>
  </id_info>
  <brief_title>EEG and TMS-based Biomarkers of ALS, MS and FTD</brief_title>
  <official_title>Investigation of EEG and TMS-based Biomarkers of Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Frontotemporal Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dublin, Trinity College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Motor Neurone Disease Association, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irish Research Council, IE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Research Board, IE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Motor Neurone, IE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thierry Latran Foundation, FR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Association, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dublin, Trinity College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to improve understanding of the biology of why&#xD;
      ALS, MS and FTD have different effects on different people and facilitate better measurement&#xD;
      of the disease in future drug testing. To do this, brain and spinal cord neural network&#xD;
      functionality will be measured over time, in addition to profiling of movement and&#xD;
      non-movement symptoms, in large groups of patients, as well as in a population-based sample&#xD;
      of the healthy population. Patterns of dysfunction which relate to patients' diagnosis and&#xD;
      coinciding and future symptoms which align with categories of patients with similar prognoses&#xD;
      will be investigated and their ability to predict incident patients' symptoms in future will&#xD;
      be measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this project is to characterize spatiotemporal patterns of central nervous system&#xD;
      dysfunction that correlate with clinical features of ALS, MS and FTD, to provide non-invasive&#xD;
      electrophysiological measurements that can be used in a clinical setting to inform&#xD;
      stratification of patients in clinical trials, and to provide data driven diagnostic and&#xD;
      prognostic biomarkers and objective clinical trial outcome measures. Such dysfunction will be&#xD;
      investigated by recording single- and paired-pulse transcranial magnetic stimulation&#xD;
      (TMS)-associated electromyography (EMG) during rest and by recording electroencephalography&#xD;
      (EEG) during rest and during cognitive-motor tasks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis-related difference in EEG or TMS measurements</measure>
    <time_frame>Baseline recording</time_frame>
    <description>Differences in single or paired pulse TMS measures or time and/or frequency domain EEG characteristics between those within each patient cohort and controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognosis-related EEG or TMS measurements</measure>
    <time_frame>Baseline recording</time_frame>
    <description>Patient cohort single or paired pulse TMS measures or time and/or frequency domain EEG characteristics which show significant correlation to cognitive, behavioural, motor and/or sensory task performance, to disease duration or to survival time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis-related changes in EEG or TMS measurements</measure>
    <time_frame>Baseline to final visit assessed up to 2 years after baseline</time_frame>
    <description>Differences in rate of change (slope) across time of single or paired pulse TMS measures or time and/or frequency domain EEG characteristics between those within each patient cohort relative to controls</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognosis-related changes in EEG or TMS measurements</measure>
    <time_frame>Baseline to final visit assessed up to 2 years after baseline</time_frame>
    <description>Rates of change (slope) across time of patient cohort single or paired pulse TMS measures or time and/or frequency domain EEG characteristics which show significant correlation to cognitive, behavioural, motor and/or sensory task performance, to disease duration or to survival time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnosis-specific changes in EEG or TMS measurements</measure>
    <time_frame>Baseline to final visit assessed up to 2 years after baseline</time_frame>
    <description>Differences in rate of change (slope) across time of single or paired pulse TMS measures or time and/or frequency domain EEG characteristics between patient cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis-specific difference in EEG or TMS measurements</measure>
    <time_frame>Baseline recording</time_frame>
    <description>Differences in single or paired pulse TMS measures or time and/or frequency domain EEG characteristics between patient cohorts</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Frontotemporal Dementia</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Individuals from the Irish population with no psychiatric, psychological, neurological or muscular disease diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amyotrophic lateral sclerosis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple sclerosis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal dementia patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>128 electrode electroencephalography (EEG)</intervention_name>
    <description>128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)</description>
    <arm_group_label>Amyotrophic lateral sclerosis patients</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Frontotemporal dementia patients</arm_group_label>
    <arm_group_label>Multiple sclerosis patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcranial magnetic stimulation (TMS)</intervention_name>
    <description>Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions</description>
    <arm_group_label>Amyotrophic lateral sclerosis patients</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Frontotemporal dementia patients</arm_group_label>
    <arm_group_label>Multiple sclerosis patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy controls and patients diagnosed with ALS, FTD or MS&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age &gt;18 years and able to give informed written or verbal (in the presence of two&#xD;
             witnesses) consent.&#xD;
&#xD;
          -  In the case of non-control subjects, a clinical diagnosis of:&#xD;
&#xD;
             (i) Probable frontotemporal dementia (FTD) including behavioural variant FTD, semantic&#xD;
             dementia or primary progressive aphasia) with supportive brain imaging or known FTD&#xD;
             causing genetic mutation (ii) Multiple sclerosis (MS) according to the McDonald&#xD;
             criteria (Polman et al., 2011) or (iii) Possible, probable or definite amyotrophic&#xD;
             lateral sclerosis (ALS) according to the El Escorial Criteria Revised (Brooks et al.&#xD;
             2000)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any diagnosed neurological/muscular disease other than ALS, MS or FTD&#xD;
&#xD;
          -  Use of neuro- or myo-modulatory medications except riluzole&#xD;
&#xD;
          -  Inability to participate due to disease-related motor symptoms (e.g. inability to sit&#xD;
             for the required time or click the mouse to respond)&#xD;
&#xD;
          -  Upper body metallic implants&#xD;
&#xD;
          -  History of seizure disorders in the participant or immediate family members&#xD;
&#xD;
          -  Anxiety-induced fainting&#xD;
&#xD;
          -  Regular migraine&#xD;
&#xD;
          -  Evidence of significant respiratory insufficiency&#xD;
&#xD;
          -  Sleep time &gt;2 hours below normal and/or alcohol consumption the night before data&#xD;
             collection (in which case, recording session will be rescheduled).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Unit of Neurology, Trinity College Dublin, The University of Dublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN</last_name>
    <phone>+353 1 896 4497</phone>
    <email>hardimao@tcd.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roisin McMackin, BA PhD</last_name>
    <phone>01 896 4497</phone>
    <email>mcmackr@tcd.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Unit of Neurology, Trinity College Dublin, The University of Dublin</name>
      <address>
        <city>Dublin</city>
        <state>Leinster</state>
        <zip>Dublin 2</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orla Hardiman, BSc MB BCh BAO MD FRCPI FAAN</last_name>
      <phone>018964497</phone>
      <email>hardimao@tcd.ie</email>
    </contact>
    <contact_backup>
      <last_name>Roisin McMackin, BA PhD</last_name>
      <phone>0894888697</phone>
      <email>mcmackr@tcd.ie</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <results_reference>
    <citation>McMackin R, Dukic S, Broderick M, Iyer PM, Pinto-Grau M, Mohr K, Chipika R, Coffey A, Buxo T, Schuster C, Gavin B, Heverin M, Bede P, Pender N, Lalor EC, Muthuraman M, Hardiman O, Nasseroleslami B. Dysfunction of attention switching networks in amyotrophic lateral sclerosis. Neuroimage Clin. 2019;22:101707. doi: 10.1016/j.nicl.2019.101707. Epub 2019 Feb 2.</citation>
    <PMID>30735860</PMID>
  </results_reference>
  <results_reference>
    <citation>Dukic S, McMackin R, Buxo T, Fasano A, Chipika R, Pinto-Grau M, Costello E, Schuster C, Hammond M, Heverin M, Coffey A, Broderick M, Iyer PM, Mohr K, Gavin B, Pender N, Bede P, Muthuraman M, Lalor EC, Hardiman O, Nasseroleslami B. Patterned functional network disruption in amyotrophic lateral sclerosis. Hum Brain Mapp. 2019 Nov 1;40(16):4827-4842. doi: 10.1002/hbm.24740. Epub 2019 Jul 26.</citation>
    <PMID>31348605</PMID>
  </results_reference>
  <results_reference>
    <citation>McMackin R, Dukic S, Costello E, Pinto-Grau M, Fasano A, Buxo T, Heverin M, Reilly R, Muthuraman M, Pender N, Hardiman O, Nasseroleslami B. Localization of Brain Networks Engaged by the Sustained Attention to Response Task Provides Quantitative Markers of Executive Impairment in Amyotrophic Lateral Sclerosis. Cereb Cortex. 2020 Jul 30;30(9):4834-4846. doi: 10.1093/cercor/bhaa076. Erratum in: Cereb Cortex. 2020 Jun 30;30(8):4727.</citation>
    <PMID>32318719</PMID>
  </results_reference>
  <results_reference>
    <citation>McMackin R, Dukic S, Costello E, Pinto-Grau M, Keenan O, Fasano A, Buxo T, Heverin M, Reilly RB, Pender N, Hardiman O, Nasseroleslami B. Sustained attention to response task-related beta oscillations relate to performance and provide a functional biomarker in ALS. J Neural Eng. 2021 Jan 4. doi: 10.1088/1741-2552/abd829. [Epub ahead of print]</citation>
    <PMID>33395671</PMID>
  </results_reference>
  <results_reference>
    <citation>Iyer PM, Mohr K, Broderick M, Gavin B, Burke T, Bede P, Pinto-Grau M, Pender NP, McLaughlin R, Vajda A, Heverin M, Lalor EC, Hardiman O, Nasseroleslami B. Mismatch Negativity as an Indicator of Cognitive Sub-Domain Dysfunction in Amyotrophic Lateral Sclerosis. Front Neurol. 2017 Aug 15;8:395. doi: 10.3389/fneur.2017.00395. eCollection 2017.</citation>
    <PMID>28861032</PMID>
  </results_reference>
  <results_reference>
    <citation>Nasseroleslami B, Dukic S, Broderick M, Mohr K, Schuster C, Gavin B, McLaughlin R, Heverin M, Vajda A, Iyer PM, Pender N, Bede P, Lalor EC, Hardiman O. Characteristic Increases in EEG Connectivity Correlate With Changes of Structural MRI in Amyotrophic Lateral Sclerosis. Cereb Cortex. 2019 Jan 1;29(1):27-41. doi: 10.1093/cercor/bhx301.</citation>
    <PMID>29136131</PMID>
  </results_reference>
  <results_reference>
    <citation>Iyer PM, Egan C, Pinto-Grau M, Burke T, Elamin M, Nasseroleslami B, Pender N, Lalor EC, Hardiman O. Functional Connectivity Changes in Resting-State EEG as Potential Biomarker for Amyotrophic Lateral Sclerosis. PLoS One. 2015 Jun 19;10(6):e0128682. doi: 10.1371/journal.pone.0128682. eCollection 2015.</citation>
    <PMID>26091258</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dublin, Trinity College</investigator_affiliation>
    <investigator_full_name>Orla Hardiman</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>EEG</keyword>
  <keyword>TMS</keyword>
  <keyword>Neurodegeneration</keyword>
  <keyword>Network</keyword>
  <keyword>Electrophysiology</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Cognitive</keyword>
  <keyword>Behavioural</keyword>
  <keyword>Motor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Raw data from this study may be made available in anonymized form upon request from qualified investigators subject to the approval by the Data Protection Office (DPO) and Office of Corporate Partnership and Knowledge Exchanges (OCPKE) in Trinity College Dublin, the University of Dublin.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Due to ethical constraint and the time required for data quality checks, data will only be made available in fully anonymised format following publication of results.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

